Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Total Liabilities (2022 - 2025)

Zentalis Pharmaceuticals has reported Total Liabilities over the past 4 years, most recently at $72.8 million for Q4 2025.

  • Quarterly results put Total Liabilities at $72.8 million for Q4 2025, down 21.89% from a year ago — trailing twelve months through Dec 2025 was $72.8 million (down 21.89% YoY), and the annual figure for FY2025 was $72.8 million, down 21.89%.
  • Total Liabilities for Q4 2025 was $72.8 million at Zentalis Pharmaceuticals, down from $74.4 million in the prior quarter.
  • Over the last five years, Total Liabilities for ZNTL hit a ceiling of $114.3 million in Q4 2023 and a floor of $72.8 million in Q4 2025.
  • Median Total Liabilities over the past 4 years was $97.2 million (2023), compared with a mean of $95.1 million.
  • Biggest five-year swings in Total Liabilities: rose 15.18% in 2023 and later dropped 29.23% in 2025.
  • Zentalis Pharmaceuticals' Total Liabilities stood at $105.3 million in 2022, then grew by 8.56% to $114.3 million in 2023, then dropped by 18.5% to $93.2 million in 2024, then fell by 21.89% to $72.8 million in 2025.
  • The last three reported values for Total Liabilities were $72.8 million (Q4 2025), $74.4 million (Q3 2025), and $77.2 million (Q2 2025) per Business Quant data.